KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Receivables - Accured (2020 - 2024)

Historic Revenue - Other for Vir Biotechnology (VIR) over the last 6 years, with Q1 2023 value amounting to $16.2 million.

  • Vir Biotechnology's Revenue - Other rose 52480.77% to $16.2 million in Q1 2023 from the same period last year, while for Mar 2023 it was $49.1 million, marking a year-over-year increase of 41168.44%. This contributed to the annual value of $35.3 million for FY2022, which is 32320.59% up from last year.
  • Per Vir Biotechnology's latest filing, its Receivables - Accured stood at $5.7 million for Q1 2024, which was up 17142.86% from $4.0 million recorded in Q4 2023.
  • Vir Biotechnology's Receivables - Accured's 5-year high stood at $5.7 million during Q1 2024, with a 5-year trough of $600000.0 in Q2 2021.
  • Its 5-year average for Receivables - Accured is $2.1 million, with a median of $1.8 million in 2022.
  • Per our database at Business Quant, Vir Biotechnology's Revenue - Other tumbled by 8048.08% in 2019 and then surged by 82347.04% in 2022.
  • Vir Biotechnology's Revenue - Other (Quarter) stood at $609000.0 in 2019, then surged by 135.3% to $1.4 million in 2020, then skyrocketed by 108.72% to $3.0 million in 2021, then surged by 823.47% to $27.6 million in 2022, then plummeted by 41.19% to $16.2 million in 2023.
  • Its Revenue - Other stands at $16.2 million for Q1 2023, versus $27.6 million for Q4 2022 and $3.1 million for Q3 2022.